Cancer Pharmacology Services
Offering a wide range of targeted oncology services and translational models. Our comprehensive platform includes:
- in vitro biochemical, biophysical, and cell-based assays, including
- 600+ human cancer cell lines
- 70+ PDX-derived cell lines
- SPR, HTRF, ELISA, and FRET techniques
- ex vivo PD analysis, including:
- histopathology services
- NGS
- Flow cytometry
- Gene/protein expression analysis
- in vivo tumor models, including:
- 320+ CDX and 1,400+ PDX models, covering 30 cancer types
- 32 drug resistant models across 11 key targets
- Transgenic mice covering 20+ targets
- 20+ PBMC/HSC humanized models
- 42 orthotopic models for 15 cancer types
- 32 metastatic models across 7 cancer types
- 88 syngeneic models covering 21 cancer types
View our extensive panel of translational oncology services
Cancer Pharmacology Services
Related Content
NK cells are effector innate lymphoid cells (ILCs) that do not require antigen-specific priming. NK cells are not only killer...
VIEW RESOURCEJoin WuXi AppTec at IMMUNOLOGY2024™. For this year’s annual meeting of the American Association of Immunologists (AAI), WuXi Biology has...
VIEW RESOURCE